Luye Life Sciences Expands Global Reach as New Boston R&D Center Opens

PRNewswire: July 17, 2017 – BOSTON, MA, U.S.A. – The Luye Life Sciences Group announced today the opening of its new Boston R&D Center, the second global R&D facility set up in the United States after the one in New Jersey. The Boston R&D Center will collaborate with multiple business divisions of the Luye Life Sciences Group including Luye Pharma, Luye Medical, and Luye Diagnostics.

As an integral part of Luye Life Sciences Group’s global R&D system, the newly built Boston R&D Center will focus on international R&D collaboration. In particular, joint efforts between Chinese and U.S. teams will accelerate the research and development of new drug candidates in key disease areas. The Boston R&D Center will act as an important center of excellence to internalize novel earlystage biopharmaceutical assets and disruptive drug delivery technologies.

Distinguished guests who graced the opening ceremony and spoke at the subsequent seminar included Prof. Robert S. Langer, who is the member of the National Academies of Sciences, Engineering, and Medicine (“the National Academies”) and who also teaches at Massachusetts Institute of Technology (MIT); and Prof. Guangping Gao, founding director of the Hoare Gene Therapy Center of the University of Massachusetts Medical School (UMMS) and president-elect of American Society of Gene and Cell Therapy (ASGCT). Both will serve as scientific advisors for the Boston R&D Center.

“The opening of our Boston R&D Center marks another milestone in the group’s exploration of pharmaceuticals,” said Dr. Youxin Li, Global R&D president of Luye Pharma Group. “Building on existing R&D platforms for the drug delivery system (DDS) and Mab biosimilars, Luye Pharma is moving toward next-generation biopharmaceutical products and intelligent drug products. With Boston’s leading position in the global biopharmaceutical industry, we look forward to laying a solid technical foundation through collaboration on new platforms and projects, to help ensure the sustainable pipeline development of Luye Life Sciences Group.” Several biotechnology companies have already expressed their interest in working with the Boston R&D Center, tracking and analyzing a number of new early-stage drugs and technologies. These projects will effectively promote and strengthen the R&D capabilities of Luye Life Sciences Group in key areas such as cancer, schizophrenia, depression, cardiovascular anomalies, and Parkinson’s disease.

As one of the major business divisions of Luye Life Sciences Group, Luye Pharma is a leading, innovation-oriented pharmaceutical company in China and also one of the first Chinese pharmaceutical companies to conduct clinical trials on the international market. Today, multiple innovative drug candidates from Luye Pharma are being studied in clinical settings for registration with the FDA.

“R&D innovation is a core engine of our globalization strategy,” said Rongbing Yang, president of Luye Pharma Group. “This Boston R&D Center allows us to further integrate our R&D resources across the world, speed up the introduction of new drugs to China, and bring our originally developed drugs to overseas markets in order to benefit more patients worldwide.”

Luye Life Sciences Group currently has operations in China, the United States, Europe, Australia, Singapore, South Korea, and Japan. Globally, the group has 15,000 employees, of which more than 60% are from outside of China. The Boston R&D Center will support the Luye Life Sciences Group to accelerate its globalization strategy and realize its vision of becoming one of the most respected global leaders in the healthcare industry through optimization and integration of global R&D resources, international talent recruitment and exchange, and cooperation on various new projects and technologies.

According to Dianbo Liu, chairman of Luye Life Sciences Group, the establishment of the Boston R&D Center is of great strategic importance. “Through this globalized platform, we look forward to building close connections with local universities, research institutes, the industry, and the financial sector,” he said. “We believe these connections will allow us to seamlessly integrate our global R&D resources with those of new partners in order to streamline innovation and realize the commercialization of high-quality biopharmaceutical products. We will continue to invest in this center, especially in terms of talent, capital, and operating processes. Ultimately, this will lead to the launch of many more innovative drugs as well as new products and technologies with real clinical value, thereby contributing to the health of all humankind.”

Founded in 1994, the Luye Life Sciences Group is committed to a mission of “professional technology serving human health.” The group is composed of three major business divisions: Luye Pharma, Luye Medical, and Luye Investment.

Luye Pharma is a leading pharmaceutical company in China, focusing on the R&D, manufacturing, and sales of innovative pharmaceutical products worldwide. Luye Pharma runs businesses in many countries and regions including China, the United States, and Europe, with over 30 marketed products. In 2016, Luye Pharma completed the acquisition of Acino’s TDS and implant business, further strengthening its R&D capability in controlled release technology. Luye Pharma currently has several new drugs with innovative delivery technologies being trialed in the United States.

Luye Medical is the medical service sector of Luye Life Sciences. Headquartered in Singapore, it is committed to becoming one of the world’s most respected leading medical companies. Luye Medical has a global presence across China, Australia, Singapore, and South Korea. It owns and operates a series of internationally renowned medical brands such as Healthe Care (Australia), AsiaMedic, Oncocare (Singapore), and Luye Ellium. Through its acquisitions and partnerships with leading healthcare organizations, Luye Medical adopts and develops world-leading technologies as well as operational and management systems. Luye Medical strives to provide integrated and high-quality healthcare services to its global customers and patients.

Luye Investment is dedicated to incubating new businesses, with a prime focus on the R&D of antibody drugs, molecular diagnostics, regenerative medicine, and health products. In 2015, Luye Investment acquired Vela Diagnostics, a Singapore-based provider of integrated molecular solutions for diagnosis. Vela Diagnostics provides equipment, tests, and data reporting solutions for real-time PCR and next-generation sequencing on an integrated platform. It will synergize with Luye Life Sciences’ current businesses to establish an entire precision medical service chain from diagnostics to treatment. In addition, Luye Investment also possesses the first human monoclonal antibody drug R&D platform and a robust pipeline of antibody drugs in research.

Founded on the R&D and manufacture of innovative drugs, led by high-end medical services, and driven by cutting-edge life sciences research, Luye Life Sciences is committed to being a full-range medical solution provider with the aim of becoming one of the most respected global leaders in the healthcare industry.